TWI727919B - 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 - Google Patents

與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 Download PDF

Info

Publication number
TWI727919B
TWI727919B TW103144705A TW103144705A TWI727919B TW I727919 B TWI727919 B TW I727919B TW 103144705 A TW103144705 A TW 103144705A TW 103144705 A TW103144705 A TW 103144705A TW I727919 B TWI727919 B TW I727919B
Authority
TW
Taiwan
Prior art keywords
unit
formula
ligand
drug
group
Prior art date
Application number
TW103144705A
Other languages
English (en)
Chinese (zh)
Other versions
TW201532616A (zh
Inventor
羅伯特 寇拉寇斯基
史考特 傑佛瑞
派翠克 布魯克
Original Assignee
美商西雅圖遺傳學公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN202010417903.5A priority Critical patent/CN111569086B/zh
Priority to IL301674A priority patent/IL301674A/en
Priority to CN201480066385.XA priority patent/CN105813653B/zh
Priority to SG10201708812YA priority patent/SG10201708812YA/en
Priority to CA2932647A priority patent/CA2932647C/en
Priority to EA201691275A priority patent/EA039120B1/ru
Priority to CN202010418302.6A priority patent/CN111558049B/zh
Priority to KR1020247000133A priority patent/KR20240010081A/ko
Priority to KR1020227030682A priority patent/KR20220127364A/ko
Priority to JP2016536776A priority patent/JP6701077B2/ja
Priority to SG10201708839VA priority patent/SG10201708839VA/en
Priority to MX2016007364A priority patent/MX385651B/es
Priority to SG10201805160UA priority patent/SG10201805160UA/en
Priority to TW103144705A priority patent/TWI727919B/zh
Priority to AU2014369019A priority patent/AU2014369019B2/en
Priority to IL290330A priority patent/IL290330B2/en
Priority to NZ760199A priority patent/NZ760199A/en
Priority to SG10201708878YA priority patent/SG10201708878YA/en
Priority to US15/106,272 priority patent/US11116847B2/en
Application filed by 美商西雅圖遺傳學公司 filed Critical 美商西雅圖遺傳學公司
Priority to PCT/US2014/071593 priority patent/WO2015095755A1/en
Priority to NZ721877A priority patent/NZ721877A/en
Priority to SG11201610465PA priority patent/SG11201610465PA/en
Priority to KR1020167017938A priority patent/KR102442906B1/ko
Publication of TW201532616A publication Critical patent/TW201532616A/zh
Priority to IL246015A priority patent/IL246015B/en
Priority to MX2021010192A priority patent/MX2021010192A/es
Priority to ZA2016/04564A priority patent/ZA201604564B/en
Priority to JP2019041218A priority patent/JP6784790B2/ja
Priority to IL268595A priority patent/IL268595B/en
Priority to JP2020109383A priority patent/JP7229202B2/ja
Priority to ZA2020/04099A priority patent/ZA202004099B/en
Priority to AU2020281140A priority patent/AU2020281140B2/en
Priority to IL282581A priority patent/IL282581B/en
Application granted granted Critical
Publication of TWI727919B publication Critical patent/TWI727919B/zh
Priority to US17/391,580 priority patent/US20220054650A1/en
Priority to AU2022283652A priority patent/AU2022283652B2/en
Priority to JP2023020516A priority patent/JP2023055973A/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW103144705A 2013-12-19 2014-12-19 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物 TWI727919B (zh)

Priority Applications (35)

Application Number Priority Date Filing Date Title
CN201480066385.XA CN105813653B (zh) 2013-12-19 2014-12-19 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
SG10201708812YA SG10201708812YA (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
CA2932647A CA2932647C (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
EA201691275A EA039120B1 (ru) 2014-12-19 2014-12-19 Метиленкарбаматные линкеры для использования с направленными конъюгатами лекарственного средства
CN202010418302.6A CN111558049B (zh) 2013-12-19 2014-12-19 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
KR1020247000133A KR20240010081A (ko) 2013-12-19 2014-12-19 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
KR1020227030682A KR20220127364A (ko) 2013-12-19 2014-12-19 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
JP2016536776A JP6701077B2 (ja) 2013-12-19 2014-12-19 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
SG10201708839VA SG10201708839VA (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted drug conjugates
MX2016007364A MX385651B (es) 2013-12-19 2014-12-19 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
SG10201805160UA SG10201805160UA (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
TW103144705A TWI727919B (zh) 2013-12-19 2014-12-19 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
AU2014369019A AU2014369019B2 (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
IL290330A IL290330B2 (en) 2013-12-19 2014-12-19 Methylene carbamate binders for use with drug-targeting conjugates
IL301674A IL301674A (en) 2013-12-19 2014-12-19 Methylene carbamate binders for use with drug-targeting conjugates
SG10201708878YA SG10201708878YA (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
CN202010417903.5A CN111569086B (zh) 2013-12-19 2014-12-19 与目标-药物偶联物并用的亚甲基氨基甲酸酯连接物
NZ760199A NZ760199A (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
KR1020167017938A KR102442906B1 (ko) 2013-12-19 2014-12-19 표적화된-약물 컨쥬게이트와 함께 사용되는 메틸렌 카바메이트 링커
NZ721877A NZ721877A (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
SG11201610465PA SG11201610465PA (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
PCT/US2014/071593 WO2015095755A1 (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
US15/106,272 US11116847B2 (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
IL246015A IL246015B (en) 2013-12-19 2016-06-05 Methylene carbamate binders for use with drug-targeting conjugates
MX2021010192A MX2021010192A (es) 2013-12-19 2016-06-06 Enlazadores de carbamato de metileno para su uso en conjugados de farmacos dirigidos.
ZA2016/04564A ZA201604564B (en) 2013-12-19 2016-07-05 Methylene carbamate linkers for use with targeted-drug conjugates
JP2019041218A JP6784790B2 (ja) 2013-12-19 2019-03-07 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
IL268595A IL268595B (en) 2013-12-19 2019-08-08 Methylene carbamate binders for use with drug-targeting conjugates
JP2020109383A JP7229202B2 (ja) 2013-12-19 2020-06-25 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
ZA2020/04099A ZA202004099B (en) 2013-12-19 2020-07-06 Methylene carbamate linkers for use with targeted-drug conjugates
AU2020281140A AU2020281140B2 (en) 2013-12-19 2020-12-04 Methylene carbamate linkers for use with targeted-drug conjugates
IL282581A IL282581B (en) 2013-12-19 2021-04-22 Methylene carbamate binders for use with drug-targeting conjugates
US17/391,580 US20220054650A1 (en) 2013-12-19 2021-08-02 Methylene Carbamate Linkers for use with Targeted-Drug Conjugates
AU2022283652A AU2022283652B2 (en) 2013-12-19 2022-12-06 Methylene carbamate linkers for use with targeted-drug conjugates
JP2023020516A JP2023055973A (ja) 2013-12-19 2023-02-14 標的化薬物結合体と使用するためのメチレンカルバメートリンカー

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361918539P 2013-12-19 2013-12-19
US61/918,539 2013-12-19
PCT/US2014/071593 WO2015095755A1 (en) 2013-12-19 2014-12-19 Methylene carbamate linkers for use with targeted-drug conjugates
TW103144705A TWI727919B (zh) 2013-12-19 2014-12-19 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物

Publications (2)

Publication Number Publication Date
TW201532616A TW201532616A (zh) 2015-09-01
TWI727919B true TWI727919B (zh) 2021-05-21

Family

ID=60450371

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103144705A TWI727919B (zh) 2013-12-19 2014-12-19 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物

Country Status (13)

Country Link
US (2) US11116847B2 (https=)
JP (4) JP6701077B2 (https=)
KR (3) KR20240010081A (https=)
CN (3) CN111569086B (https=)
AU (3) AU2014369019B2 (https=)
CA (1) CA2932647C (https=)
IL (5) IL290330B2 (https=)
MX (2) MX385651B (https=)
NZ (1) NZ721877A (https=)
SG (1) SG11201610465PA (https=)
TW (1) TWI727919B (https=)
WO (1) WO2015095755A1 (https=)
ZA (2) ZA201604564B (https=)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
WO2016141230A1 (en) 2015-03-05 2016-09-09 Sirenas Llc Cyclic peptide analogs and conjugates thereof
KR102847350B1 (ko) 2015-11-25 2025-08-19 주식회사 리가켐바이오사이언스 분지된 링커를 포함하는 항체-약물 접합체 및 이의 제조방법
AU2016359234B2 (en) 2015-11-25 2022-09-08 Ligachem Biosciences Inc. Conjugates comprising peptide groups and methods related thereto
HRP20240795T1 (hr) 2015-11-25 2024-09-13 Ligachem Biosciences Inc. Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
US10913780B2 (en) 2016-03-24 2021-02-09 The Administrators Of The Tulane Educational Fund Conjugates, their compositions, their uses, and their methods of making
KR20180134351A (ko) * 2016-03-25 2018-12-18 시애틀 지네틱스, 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
MX2019001302A (es) * 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
WO2018045245A1 (en) 2016-09-02 2018-03-08 Sirenas Llc Cyclic peptide analogs and conjugates thereof
TWI835714B (zh) 2016-10-18 2024-03-21 美商思進公司 菸鹼醯胺腺嘌呤二核苷酸補救合成(salvage pathway)抑制劑之靶向投遞
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
EP3559039A1 (en) 2016-12-22 2019-10-30 Università Degli Studi Magna Graecia Catanzaro A monoclonal antibody targeting a unique sialoglycosilated cancer-associated epitope of cd43
WO2018124758A2 (ko) * 2016-12-28 2018-07-05 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
KR20250171447A (ko) 2017-02-28 2025-12-08 이뮤노젠 아이엔씨 자기희생적 펩티드 링커 및 이들의 접합체를 갖는 메이탄시노이드 유도체
EP4011396A1 (en) * 2017-03-10 2022-06-15 QuiaPEG Pharmaceuticals AB Releasable conjugates
AU2018237683A1 (en) * 2017-03-24 2019-10-31 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
MX2019011655A (es) 2017-03-29 2019-12-19 Legochem Biosciences Inc Profarmaco de dimero de pirrolobenzodiazepina y compuesto conjugado ligando-conector de este.
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
CA3061907A1 (en) * 2017-05-02 2018-11-08 Revolution Medicines, Inc. Rapamycin analogs as mtor inhibitors
WO2019051489A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
WO2019051488A1 (en) 2017-09-11 2019-03-14 Sperovie Biosciences, Inc. COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISEASE
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
CA3079215A1 (en) 2017-10-24 2019-05-02 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+ cells
WO2019084060A1 (en) 2017-10-24 2019-05-02 Silverback Therapeutics, Inc. CONJUGATES AND METHODS OF USE FOR THE SELECTIVE DELIVERY OF IMMUNOMODULATORY AGENTS
WO2019108863A1 (en) 2017-11-29 2019-06-06 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd5+ cells
WO2019118884A1 (en) 2017-12-15 2019-06-20 Silverback Therapeutics, Inc. Antibody construct-drug conjugate for the treatment of hepatitis
EP3728280B1 (en) * 2017-12-21 2023-06-28 Pharmacytics B.V. Method for improving the oral bioavailability of a drug
KR20200121800A (ko) 2018-01-05 2020-10-26 싸이브렉사 1, 인크. 산성 또는 저산소성 질환에 걸린 조직에 관련된 질환의 치료를 위한 화합물, 조성물 및 방법
TW202003044A (zh) * 2018-03-09 2020-01-16 瑞典商奎亞培格製藥公司 可釋放之抗體結合物
CA3094313A1 (en) * 2018-04-06 2019-10-10 Seattle Genetics, Inc. Camptothecin peptide conjugates
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
JP7459063B2 (ja) 2018-05-09 2024-04-01 レゴケム バイオサイエンシズ， インク． 抗－ｃｄ１９抗体薬物複合体に関連する組成物および方法
WO2019222272A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
WO2019234136A1 (en) 2018-06-05 2019-12-12 King's College London Btnl3/8 targeting constructs for delivery of payloads to the gastrointestinal system
TWI851577B (zh) * 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
AU2019337654A1 (en) 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
AU2019340472A1 (en) * 2018-09-12 2021-04-01 Quiapeg Pharmaceuticals Ab Releasable GLP-1 conjugates
MA53765B2 (fr) 2018-12-21 2025-04-30 Regeneron Pharmaceuticals, Inc. Tubulysines et conjugués tubulysines-protéines
SG11202110287QA (en) 2019-04-24 2021-10-28 Heidelberg Pharma Res Gmbh Amatoxin antibody-drug conjugates and uses thereof
CN113811333B (zh) 2019-05-14 2024-03-12 诺维逊生物股份有限公司 靶向抗癌核激素受体的化合物
TW202116356A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩三號公司 作為治療劑之微管靶向藥劑之肽結合物
CN114341162B (zh) 2019-07-10 2025-10-17 赛博克萨2公司 作为治疗剂的细胞毒素的肽缀合物
WO2021030665A1 (en) 2019-08-15 2021-02-18 Silverback Therapeutics, Inc. Formulations of benzazepine conjugates and uses thereof
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
AU2020356955A1 (en) * 2019-10-04 2022-04-14 Seagen Inc. Camptothecin peptide conjugates
WO2021072203A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Tgfbetar1 inhibitor-asgr antibody conjugates and uses thereof
WO2021072330A1 (en) 2019-10-09 2021-04-15 Silverback Therapeutics, Inc. Galnac-tgfbr1 inhibitor conjugates for the treatment of liver diseases
WO2021092287A1 (en) 2019-11-08 2021-05-14 North Carolina State University Cross-linking compounds and methods of use thereof
WO2021097046A1 (en) 2019-11-13 2021-05-20 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN110974975B (zh) * 2019-12-12 2023-10-20 成都百利多特生物药业有限责任公司 一种快速释放的抗体药物偶联物
CN114569735A (zh) * 2020-12-01 2022-06-03 泰州复旦张江药业有限公司 一种连接基-药物偶联物、制备方法及应用
EP4257153B1 (en) * 2020-12-04 2025-11-12 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. Antibody-drug conjugate, and intermediate thereof, preparation method therefor, and application thereof
KR20230121842A (ko) * 2020-12-18 2023-08-21 상하이 후단-장지앙 바이오-파마슈티컬 컴퍼니 리미티드 Trop2를 표적으로 하는 항체 약물 접합체, 이의 제조방법 및 용도
EP4265274B1 (en) * 2020-12-18 2025-03-19 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. B7-h3 targeting antibody-drug conjugate, and preparation method therefor and use thereof
MX2023007126A (es) 2020-12-23 2023-09-04 Univ Muenchen Ludwig Maximilians Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos.
KR20230160299A (ko) 2021-03-23 2023-11-23 누베이션 바이오 인크. 항암 핵 호르몬 수용체 표적화 화합물
AU2022253474A1 (en) 2021-04-08 2023-11-16 Board Of Regents, The University Of Texas System Compounds and methods for theranostic targeting of parp activity
JP7717832B2 (ja) 2021-04-10 2025-08-04 ジェンマブ エー／エス Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法
WO2022226317A1 (en) 2021-04-23 2022-10-27 Profoundbio Us Co. Anti-cd70 antibodies, conjugates thereof and methods of using the same
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
TW202320857A (zh) 2021-07-06 2023-06-01 美商普方生物製藥美國公司 連接子、藥物連接子及其結合物及其使用方法
TW202320858A (zh) 2021-07-19 2023-06-01 美商薩諾管理公司 免疫接合物及方法
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
WO2023092099A1 (en) 2021-11-19 2023-05-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
EP4460330A1 (en) * 2022-01-06 2024-11-13 Virtuoso Binco, Inc. Conjugates, compositions and methods of use
AU2023251200A1 (en) 2022-04-07 2024-10-03 Heidelberg Pharma Research Gmbh Methods of improving the therapeutic index of amatoxin-antibody conjugates
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
KR20250031149A (ko) 2022-06-30 2025-03-06 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
WO2024025396A1 (ko) * 2022-07-28 2024-02-01 주식회사 레고켐 바이오사이언스 신규 오리스타틴 전구약물
JP2025530213A (ja) 2022-09-09 2025-09-11 ミリックス ファーマ リミテッド Ｎｍｔ阻害剤を含む抗体薬物コンジュゲート及びその使用
TWI903241B (zh) * 2022-09-30 2025-11-01 美商西雅圖免疫公司 一種帶有高穩定性親水連接單元的奧瑞他汀類藥物及其偶聯物
WO2024121632A1 (en) 2022-12-09 2024-06-13 Crispr Therapeutics Ag Use of anti-cd117 antibody drug conjugate (adc)
CN120936385A (zh) 2023-03-13 2025-11-11 海德堡医药研究有限责任公司 用于在癌症治疗中使用的皮下施用的抗体-药物缀合物
KR20240159447A (ko) 2023-04-28 2024-11-05 주식회사 에이비켐바이오 말레이미드 함유 링커-페이로드 접합체
KR20240159448A (ko) 2023-04-28 2024-11-05 주식회사 에이비켐바이오 균일한 dar를 갖는 신규한 항체-약물 중합체의 제조방법
KR20250074353A (ko) 2023-11-20 2025-05-27 주식회사 에이비켐바이오 높은 dar를 갖는 신규한 항체-약물 중합체, 이의 제조방법 및 이의 용도
EP4543314A1 (en) * 2023-06-22 2025-04-30 Cilag GmbH International Systems and methods for embedding medical additives into bioabsorbable materials
US20240423619A1 (en) 2023-06-22 2024-12-26 Cilag Gmbh International Surgical adjuncts including fluid barriers
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
CN119424671A (zh) * 2023-08-01 2025-02-14 上海新理念生物医药科技有限公司 含糖基吡啶型连接子的抗体药物偶联物
AU2024339683A1 (en) 2023-09-13 2026-03-26 Toray Industries, Inc. Pharmaceutical composition for treating, preventing and/or diagnosing cancer
AU2024353316A1 (en) 2023-09-26 2026-03-26 Genmab A/S Ptk7 binding agents, conjugates thereof and methods of using the same
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149661A1 (en) 2024-01-10 2025-07-17 Genmab A/S Slitrk6 binding agents, conjugates thereof and methods of using the same
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025181219A1 (en) 2024-02-29 2025-09-04 Genmab A/S Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same
WO2026039642A1 (en) 2024-08-16 2026-02-19 Ardeagen Corporation Anti-mesothelin antibody conjugates and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
CN103025165A (zh) * 2010-05-05 2013-04-03 普罗林科斯有限责任公司 自大分子共轭物的控释

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927070A (en) * 1972-05-08 1975-12-16 Karoly Szabo M-(3,3-disubstituted ureido) phenyl {8 (substituted)methyl{9 {0 carbamates
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
WO1997009066A1 (en) * 1995-09-08 1997-03-13 Kanebo, Ltd. Fas LIGAND SOLUBILIZATION INHIBITOR
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
WO2001036003A2 (en) 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
MXPA06010782A (es) * 2004-03-23 2007-03-28 Complex Biosystems Gmbh Ligador de profarmaco.
HUE035853T2 (en) * 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
JP2011505146A (ja) * 2007-11-30 2011-02-24 ブリストル−マイヤーズ スクイブ カンパニー タンパク質チロシンキナーゼ７（ｐｔｋ７）を対象とするモノクローナル抗体−パートナー分子複合体
US20110152252A1 (en) * 2007-12-18 2011-06-23 Institut Curie Shiga toxin b-subunit/chemotherapeutics conjugates
US8742076B2 (en) * 2008-02-01 2014-06-03 Genentech, Inc. Nemorubicin metabolite and analog reagents, antibody-drug conjugates and methods
WO2009158668A1 (en) 2008-06-26 2009-12-30 Prolynx Llc Prodrugs and drug-macromolecule conjugates having controlled drug release rates
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
EP2566334B1 (en) * 2010-05-05 2018-04-18 Prolynx, LLC Controlled drug release from solid supports
ES2945932T3 (es) 2011-10-14 2023-07-10 Seagen Inc Pirrolobenzodiazepinas y conjugados dirigidos
WO2013055993A1 (en) 2011-10-14 2013-04-18 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
CA2850103C (en) 2011-10-14 2019-09-10 Spirogen Sarl Pyrrolobenzodiazepines
KR102557309B1 (ko) 2012-05-15 2023-07-20 씨젠 인크. 자가-안정화 링커 접합체
MX340090B (es) * 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US9695189B2 (en) 2013-03-01 2017-07-04 Mark Quang Nguyen Chemical crosslinkers and compositions thereof
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
WO2016141230A1 (en) 2015-03-05 2016-09-09 Sirenas Llc Cyclic peptide analogs and conjugates thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
CN103025165A (zh) * 2010-05-05 2013-04-03 普罗林科斯有限责任公司 自大分子共轭物的控释

Also Published As

Publication number Publication date
US11116847B2 (en) 2021-09-14
IL301674A (en) 2023-05-01
NZ721877A (en) 2022-07-29
IL246015A0 (en) 2016-07-31
IL290330A (en) 2022-04-01
JP2023055973A (ja) 2023-04-18
CN105813653A (zh) 2016-07-27
AU2022283652B2 (en) 2024-10-03
US20160303254A1 (en) 2016-10-20
CN105813653B (zh) 2020-06-26
KR102442906B1 (ko) 2022-09-14
CN111569086B (zh) 2024-06-21
IL290330B2 (en) 2023-09-01
JP7229202B2 (ja) 2023-02-27
CA2932647A1 (en) 2015-06-25
IL282581B (en) 2022-03-01
CA2932647C (en) 2022-06-14
KR20160098303A (ko) 2016-08-18
KR20220127364A (ko) 2022-09-19
IL268595A (en) 2019-10-31
ZA201604564B (en) 2022-09-28
AU2014369019A1 (en) 2016-07-21
AU2014369019B2 (en) 2020-09-17
CN111569086A (zh) 2020-08-25
CN111558049B (zh) 2024-06-21
JP2020152733A (ja) 2020-09-24
KR20240010081A (ko) 2024-01-23
IL246015B (en) 2020-03-31
TW201532616A (zh) 2015-09-01
MX385651B (es) 2025-03-18
IL290330B1 (en) 2023-05-01
MX2016007364A (es) 2016-09-08
ZA202004099B (en) 2023-12-20
AU2022283652A1 (en) 2023-02-02
SG11201610465PA (en) 2017-01-27
WO2015095755A1 (en) 2015-06-25
JP2017500299A (ja) 2017-01-05
AU2020281140B2 (en) 2022-09-08
IL282581A (en) 2021-06-30
JP6701077B2 (ja) 2020-05-27
MX2021010192A (es) 2021-09-21
IL268595B (en) 2021-05-31
AU2020281140A1 (en) 2021-01-07
CN111558049A (zh) 2020-08-21
JP6784790B2 (ja) 2020-11-11
JP2019081813A (ja) 2019-05-30
US20220054650A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
TWI727919B (zh) 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
TWI777502B (zh) 與標的-藥物結合物併用之亞甲基胺基甲酸酯連接物
HK40035889A (en) Methylene carbamate linkers for use with targeted-drug conjugates
HK40035888A (en) Methylene carbamate linkers for use with targeted-drug conjugates
HK40096533A (en) Methylene carbamate linkers for use with targeted-drug conjugates
NZ760199A (en) Methylene carbamate linkers for use with targeted-drug conjugates
HK1229248B (en) Methylene carbamate linkers for use with targeted-drug conjugates
HK1229248A1 (en) Methylene carbamate linkers for use with targeted-drug conjugates
EA039120B1 (ru) Метиленкарбаматные линкеры для использования с направленными конъюгатами лекарственного средства

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees